Shilpa Medicare Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Shilpa Medicare Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $300.5K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Shilpa Medicare Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $300.5K Trade | TransData Nexus

Shilpa Medicare Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $300.5K Total Trade · DGFT Verified

Shilpa Medicare Limited is an Indian pharmaceutical exporter with a total trade value of $300.5K across 2 products in 1 therapeutic categories. Based on 8 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Busulfan ($150.5K), Pemetrexed ($150.0K), .

Shilpa Medicare Limited — Export Portfolio & Destination Treemap

Shilpa Medicare Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Shilpa Medicare Limited? — Company Overview & Market Position

Shilpa Medicare Limited, established in 1987, is a prominent Indian pharmaceutical company specializing in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is headquartered in Raichur, Karnataka, India, with its registered office located at #12-6-214/A1, Hyderabad Road, Raichur, Karnataka 584135. Shilpa Medicare Limited is publicly listed on the National Stock Exchange of India (NSE) under the ticker symbol SHILPAMED and on the Bombay Stock Exchange (BSE) under the code 530549. The company's Corporate Identification Number (CIN) is L85110KA1987PLC008739. As of the latest available data, Shilpa Medicare Limited employs approximately 998 individuals. The company's official website is www.vbshilpa.com.

What Does Shilpa Medicare Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Busulfan$150.5K 2Pemetrexed$150.0K

Product Portfolio — Top 2 by Export Value

Shilpa Medicare Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Busulfan	Advanced Oncology	$150.5K	5	3.1%	5
2	Pemetrexed	Advanced Oncology	$150.0K	3	0.5%	7

Shilpa Medicare Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $300.5K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Shilpa Medicare Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Shilpa Medicare Limited operates multiple manufacturing facilities across India, with a significant presence in Raichur, Karnataka, and Jadcherla, Telangana. The Jadcherla facility, known as Unit IV, specializes in the production of sterile injectables, oral tablets, and capsules. This facility underwent a ten-day inspection by the US Food and Drug Administration (FDA) in November 2025, resulting in eight inspectional observations, none of which were classified as repeat violations. The company has also received approvals from major international regulators, including the European Medicines Agency (EMA), Health Canada, and the Therapeutic Goods Administration (TGA) of Australia.

3Key Leadership

The leadership team at Shilpa Medicare Limited is headed by Managing Director and Director Vishnukant Chaturbhuj Bhutada. Other key executives include Sharath Reddy Kalakota, Vice President of Projects and Operations and Whole-Time Director; Alpesh Maheshkumar Dalal, Chief Financial Officer; Pramod Kumar, Senior Vice President of Technical; Monish Shah, Head of Investor Relations; Ritu Tiwary, Company Secretary and Compliance Officer; P. V. Narasimha Rao, Chief Human Resource Officer; Vinay Konaje, Business Head of Biologics; Rajyashri Karur Ramakrishnan, Chief Scientific Officer of Biologicals; and Dr. Jayant Karajgi, Chief Operating Officer of Formulations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Shilpa Medicare Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Shilpa Medicare Limited has established a significant presence in regulated markets, including the United States, Europe, the United Kingdom, and Australia. The company's products are approved by major international regulatory bodies, such as the FDA, EMA, and TGA. In the United States, Shilpa Medicare Limited has received tentative approvals for generic versions of dimethyl fumarate and tenofovir alafenamide, indicating its commitment to expanding its footprint in the U.S. market. The company's manufacturing facilities have also been inspected and approved by the FDA, EMA, Health Canada, and TGA, ensuring compliance with international quality standards.

2Emerging Markets

Shilpa Medicare Limited has made strategic inroads into emerging markets, including Africa, Latin America, and Southeast Asia. The company's products are available in various countries across these regions, facilitated by its adherence to international quality standards and regulatory approvals. The company's commitment to quality is further demonstrated by its compliance with the World Health Organization's (WHO) prequalification program, which enables access to these emerging markets.

3Geographic Strategy

Shilpa Medicare Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Shilpa Medicare Limited's manufacturing facilities have been inspected by the FDA, with the Jadcherla facility receiving eight inspectional observations in November 2025. The company has also received tentative approvals for generic versions of dimethyl fumarate and tenofovir alafenamide, indicating its commitment to expanding its footprint in the U.S. market. The company's facilities are registered with the FDA, and it has filed Abbreviated New Drug Applications (ANDAs) for various products. Shilpa Medicare Limited's adherence to FDA regulations underscores its commitment to maintaining high-quality manufacturing standards.

2WHO & EU GMP

Shilpa Medicare Limited's manufacturing facilities comply with the World Health Organization's Good Manufacturing Practices (WHO GMP) and the European Union's Good Manufacturing Practices (EU GMP). The company's adherence to these standards ensures that its products meet international quality benchmarks, facilitating access to global markets. The company's compliance with WHO GMP and EU GMP underscores its commitment to maintaining high-quality manufacturing standards.

3CDSCO & Indian Regulatory

Shilpa Medicare Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Shilpa Medicare Limited operates in a competitive landscape, with several key players in the pharmaceutical industry. The company's focus on oncology and non-oncology APIs, as well as its commitment to quality manufacturing, positions it favorably in the market. The company's adherence to international quality standards and regulatory approvals further strengthens its competitive position. Shilpa Medicare Limited's strategic focus on diversification and global expansion allows it to leverage growth opportunities in various regions while maintaining a balanced risk profile.

2Key Differentiators

Shilpa Medicare Limited's key differentiators include its specialization in oncology and non-oncology APIs, commitment to quality manufacturing, and adherence to international regulatory standards. The company's focus on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, distinguishes it from competitors that primarily focus on active pharmaceutical ingredients (APIs). Shilpa Medicare Limited's global presence and strategic focus on diversification further enhance its competitive advantages.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Shilpa Medicare Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Shilpa Medicare Limited has a track record of consistent export performance, with a total export value of $300,000 USD across eight shipments from 2022 to 2026. The company's portfolio is concentrated, with its top five products accounting for 100% of its exports. The primary products exported include Busulfan and Pemetrexed, each contributing $150,000 USD to the total export value. The company's adherence to international quality standards and regulatory approvals underscores its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Shilpa Medicare Limited as a supplier

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Shilpa Medicare Limited

How many pharmaceutical products does Shilpa Medicare Limited export from India?

Shilpa Medicare Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Busulfan ($150.5K), Pemetrexed ($150.0K). Total export value is $300.5K.

What is Shilpa Medicare Limited's total pharmaceutical export value?

Shilpa Medicare Limited's total pharmaceutical export value is $300.5K, based on 8 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Shilpa Medicare Limited cover?

Shilpa Medicare Limited exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 2 products).

Get Full Shilpa Medicare Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.